Hospital Hietzing: Clinical Trials

20 trials sponsored by Hospital Hietzing, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 5 unknown, 1 terminated. 4 Phase 4, 3 Phase 3, 2 Not applicable, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 44Completed 4
Phase 33Unknown 2, Terminated 1
Not applicable2Completed 1, Unknown 1
Phase 22Terminated 1, Unknown 1

Follow Hospital Hietzing: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases
Age Related Macular Degeneration (ARMD), Retinal Vein Occlusion (RVO)
CompletedHospital Hietzing3932023-05-012026-04-07
Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis
Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) - Rheumatoid Arthritis
Not applicableUnknownMedical University of Vienna852022-03-012021-11-15
Effect of Ciclosporin Eyedrops on Sjögren Syndrome
Cyclosporin, Hydrocortisone - Dry Eye Syndromes
Not applicableCompletedHospital Hietzing122020-08-312021-04-08
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care - COVID-19
Phase 2 / Phase 3UnknownMedical University of Vienna5002020-04-162021-03-02
Preoperative Anaemia prevaLence In surgiCal patiEnts
Anemia, Iron-deficiency
CompletedJohann Wolfgang Goethe University Hospital25002019-08-152025-08-07
Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser
Ranibizumab 0.5 MG/0.05 ML Intraocular Solution - Diabetic Retinal Edema
Phase 4CompletedHospital Hietzing502017-04-022018-07-18
Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth Factor
OCT - Neovascular Age-related Macular Degeneration
CompletedHospital Hietzing182016-05-302018-09-20
Long-term Intraocular Lens (IOL) Decentration and Tilt in Eyes With Pseudoexfoliation Syndrome (PES) Following Cataract Surgery
no intervention - Cataract, Pseudoexfoliation Syndrome
CompletedHospital Hietzing372016-04-012018-03-08
Spherical Aberration on the Optical of Two Different Aspherical Intraocular Lenses
intraocular lens - Cataract
CompletedHospital Hietzing602015-09-012017-07-21
Intravitreal Anti-vascular Endothelial Growth Factor Administration and Its Influence on Vitreomacular Interface- and Retinal Morphology in Eyes With Neovascular Age-related Macular Degeneration
OCT - Vitreomacular Interface
CompletedHospital Hietzing432015-02-022018-09-21
The Clinical Importance of Angle Alpha by Multifocal Intraocular Lenses.
Cataract surgery - IOL, Cataract
CompletedHospital Hietzing652014-10-012020-02-21
Clinical Analysis of Two Toric Intraocular Lenses
intraocular lenses - Cataract, IOL
CompletedHospital Hietzing602012-06-012017-12-13
Acute Anterior Uveitis: Psychic Burden and Pain
Filling in a patient questionnaire - Anterior Uveitis
UnknownHospital Hietzing352010-05-012011-11-29
Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification
cataract surgery - Cataract
Phase 4CompletedHospital Hietzing402008-12-012010-08-17
Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration
Ranibizumab, Bevacizumab - Age Related Macular Degeneration
Phase 3UnknownThe Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery3202008-07-012010-06-09
Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.
Polylens Y30 intraocular lens, Orange Series Model PC 440 Y intraocular lens - Cataract
Phase 4CompletedHospital Hietzing322008-05-012010-08-17
Efficacy of Inspiratory Muscle Training on Inspiratory Capacity in Patients With COPD
COPD
UnknownHospital Hietzing2007-05-012008-05-22
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
infliximab, placebo - Lupus Erythematosus, Systemic, Lupus Nephritis
Phase 2 / Phase 3TerminatedMedical University of Vienna12006-09-012009-10-05
Quality of Life in Juvenile Patients With Uveitis
Filling in a psychometric questionnaire - Uveitis
CompletedHospital Hietzing372006-01-012011-12-23
Yellow Versus White Study
cataract surgery (Hoya AF-1 [UY] YA-60BB), cataract surgery (Hoya AF-1 [UV] VA-60BB lens) - Cataract
Phase 4CompletedHospital Hietzing242005-12-012008-02-12

Conditions studied

Cataract (7)  ·  Macular Degeneration (2)  ·  Anemia (1)  ·  Anemia, Iron-Deficiency (1)  ·  Arthritis, Rheumatoid (1)  ·  COVID-19 (1)  ·  Coitus (1)  ·  Dry Eye Syndromes (1)  ·  Exfoliation Syndrome (1)  ·  Folic Acid Deficiency (1)  ·  Intraocular Lymphoma (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Lupus Nephritis (1)  ·  Nephritis (1)  ·  Proteinuria (1)

Interventions

Cataract Extraction (3)  ·  Infliximab (2)  ·  Lenses, Intraocular (2)  ·  Ranibizumab (2)  ·  Bevacizumab (1)  ·  Certolizumab Pegol (1)  ·  Chloroquine (1)  ·  Cyclosporine (1)  ·  Etanercept (1)  ·  GLPG0634 (1)  ·  Hydrocortisone (1)  ·  Hydroxychloroquine (1)  ·  Interleukin 1 Receptor Antagonist Protein (1)  ·  Lopinavir (1)  ·  Rivaroxaban (1)

Countries

Austria (12)  ·  Germany (2)  ·  Netherlands (1)

Top investigators

Matthias G Wirtitsch, MD (2)  ·  Nadja Karnik, MD (2)  ·  Saskia M Maca, MD (2)  ·  Bernd Jilma, MD (1)  ·  Falk Hiepe, MD (1)  ·  Josef S Smolen, MD (1)  ·  Marc Bijl, MD (1)  ·  Martin Aringer, MD (1)  ·  Michael Reiter (1)

Results publications

PMID 23233798, PMID 23292928, PMID 28900544, PMID 29607216, PMID 33471202, PMID 34473343, PMID 35141170, PMID 35935856, PMID 36220325, PMID 40269760, PMID 41240945